Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
| Revenue (TTM) | 1,000 |
| Gross Profit (TTM) | 1,000 |
| EBITDA | $-11.69M |
| Operating Margin | 0.00% |
| Return on Equity | -320.70% |
| Return on Assets | -105.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.73 |
| Price-to-Book | 1.35 |
| Price-to-Sales (TTM) | 7.23 |
| EV/Revenue | 11.47 |
| EV/EBITDA | -0.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -94.10% |
| Shares Outstanding | $1.17M |
| Float | $1.20M |
| % Insiders | 29.82% |
| % Institutions | 2.18% |
Volatility is currently contracting
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass.
Video webcast now available here
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ERNA and any ticker you trade — then tracks every position and per-strategy win rate.
